Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000145.xml
Dialyse aktuell 2021; 25(07): 250-254
DOI: 10.1055/a-1401-3142
DOI: 10.1055/a-1401-3142
Expertentipp
Neue Therapieansätze in der LDL-Cholesterin-Absenkung?
Lipidsenker
Erhöhte LDL-C-Konzentrationen (LDL-C: Low-Density-Lipoprotein-Cholesterin) sind weiterhin zweifellos ein kausaler Risikofaktor für kardiovaskuläre Ereignisse (ASCVD) [1]. In der Vergangenheit konnte mehrfach in großen randomisierten prospektiven Studien gezeigt werden, dass durch therapeutische LDL-C-Absenkungen parallel weitere kardiovaskuläre Ereignisse vermindert werden [2]. Aus all diesen Studien konnten nun in Abhängigkeit vom kardiovaskulären Risikoprofil LDL-C-Zielwerte definiert werden.
Publication History
Article published online:
10 September 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Ference BA, Ginsberg HN, Graham I. et al Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459-2472 DOI: 10.1093/eurheartj/ehx144.
- 2 Preiss D, Tobert JA, Hovingh GK. et al Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar. J Am Coll Cardiol 2020; 75: 1945-1955 DOI: 10.1016/j.jacc.2019.11.072.
- 3 Hooper AJ, Burnett JR. Recent developments in the genetics of LDL deficiency. Curr Opin Lipidol 2013; 24: 111-115 DOI: 10.1097/MOL.0b013e32835ca0d9.
- 4 Julius U, Kuss S, Tselmin S. et al Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?. J Cardiovasc Dev Dis 2020; 07: 25 DOI: 10.3390/jcdd7030025.
- 5 Mohamed F, Botha TC, Raal FJ. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr Opin Lipidol 2021; 32: 213-218 DOI: 10.1097/MOL.0000000000000755.
- 6 Carmena R, Ascaso JF, Redon J. Chronic kidney disease as a cardiovascular risk factor. J Hypertens 2020; 38: 2110-2121 DOI: 10.1097/HJH.0000000000002506.
- 7 Mach F, Baigent C, Catapano AL. et al 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188 DOI: 10.1093/eurheartj/ehz455.
- 8 Ray KK, Molemans B, Schoonen WM. et al EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2020 Aug 28 zwaa047 DOI: 10.1093/eurjpc/zwaa047 [in press]
- 9 Johannesen CDL, Mortensen MB, Langsted A. et al Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol 2021; 77: 1439-1450 DOI: 10.1016/j.jacc.2021.01.027.
- 10 Ballantyne CM, Bays H, Catapano AL. et al Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther 2021; 35: 853-864 DOI: 10.1007/s10557-021-07147-5.
- 11 Nordestgaard BG, Nicholls SJ, Langsted A. et al Advances in lipid-lowering therapy through gene-silencing technologies. Nat Rev Cardiol 2018; 15: 261-272 DOI: 10.1038/nrcardio.2018.3.
- 12 Sabatine MS, Giugliano RP, Keech AC. et al Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-1722 DOI: 10.1056/NEJMoa1615664.
- 13 Schwartz GG, Steg PG, Szarek M. et al Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379: 2097-2107 DOI: 10.1056/NEJMoa1801174.
- 14 Laina A, Gatsiou A, Georgiopoulos G. et al RNA Therapeutics in Cardiovascular Precision Medicine. Front Physiol 2018; 09: 953 DOI: 10.3389/fphys.2018.00953.
- 15 Wright RS, Ray KK, Raal FJ. et al Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol 2021; 77: 1182-1193 DOI: 10.1016/j.jacc.2020.12.058.
- 16 Markham A. Evinacumab: First Approval. Drugs 2021; 81: 1101-1105 DOI: 10.1007/s40265-021-01516-y.
- 17 Gaudet D, Gipe DA, Pordy R. et al ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. N Engl J Med 2017; 377: 296-297 DOI: 10.1056/NEJMc1705994.
- 18 Raal FJ, Rosenson RS, Reeskamp LF. et al Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med 2020; 383: 711-720 DOI: 10.1056/NEJMoa2004215.